Gaudium IVF Reports Robust FY26 Growth, Eyes Major Expansion

FY26 Revenue: ₹104.35 crore (47.56% YoY growth)
FY26 EBITDA: ₹37.70 crore (31.69% YoY growth)

Reader Takeaway: Strong revenue growth and margin expansion driven by volume and tech, with a clear expansion plan.

What just happened

Gaudium IVF and Women Health Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant 47.56% year-on-year (YoY) growth in its consolidated revenue for FY26, reaching ₹104.35 crore. EBITDA for the fiscal year increased by 31.69% YoY to ₹37.70 crore. In the fourth quarter of FY26 (Q4FY26), revenue grew 12.74% YoY to ₹30.35 crore, while EBITDA margin improved to 40.10% from 32.39% in Q4FY25.

Why this matters

This performance indicates strong business momentum and successful scaling for Gaudium IVF. The revenue growth signals increasing demand for its services, while the improved EBITDA margins suggest enhanced operational efficiency and profitability. The company's strategic focus on expansion and technological integration, particularly AI in embryology, positions it for future growth in the expanding Indian fertility market.

The backstory

The company has been focusing on increasing patient volumes at its established centres and maintaining high clinical success rates. The recent financial year saw a consolidated revenue of ₹104.35 crore, a notable jump from ₹70.72 crore in FY25. Profit After Tax (PAT) for FY26 was ₹24.48 crore, up 27.69% from FY25's ₹19.17 crore.

What changes now

Gaudium IVF has outlined an ambitious expansion plan, aiming to establish 10 new hubs in FY27, followed by 8 in FY28 and 1 in FY29, utilizing proceeds from its IPO. This expansion will focus on penetrating Tier-II markets and reinforcing existing metro operations. Additionally, the company has integrated AI-led embryology platforms (SiD and ERICA) in April 2026 to improve embryo selection consistency.

Risks to watch

While the expansion plan is aggressive, successful execution and timely stabilization of new hubs will be critical. Maintaining high clinical success rates amidst rapid scaling and competition will also be important. The integration of new technologies needs to translate into sustained patient outcomes and retention.

Peer comparison

Gaudium IVF operates in the growing fertility and women's health sector in India. Competitors include other IVF chains and standalone clinics focusing on assisted reproductive technologies. The company highlights a 58% pregnancy success rate on the first attempt as a key differentiator.

Context metrics (time-bound)

For FY26, Gaudium IVF reported revenue of ₹104.35 crore, a 47.56% increase from ₹70.72 crore in FY25. EBITDA for FY26 was ₹37.70 crore, up from ₹28.63 crore in FY25. Q4FY26 PAT was ₹8.36 crore, a 29.46% YoY rise.

What to track next

Investors will be keen to monitor the progress of the new hub rollouts in FY27 and their contribution to revenue. The impact of AI integration on clinical outcomes and patient acquisition, as well as overall market share growth, will be key metrics to track.